StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research report released on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Separately, Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price objective for the company in a research report on Thursday, July 11th.
View Our Latest Research Report on BCLI
Brainstorm Cell Therapeutics Price Performance
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). During the same period last year, the business posted ($0.27) earnings per share. On average, sell-side analysts anticipate that Brainstorm Cell Therapeutics will post -0.19 EPS for the current fiscal year.
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors own 14.33% of the company’s stock.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Featured Articles
- Five stocks we like better than Brainstorm Cell Therapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- 3 REITs to Buy and Hold for the Long Term
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- How is Compound Interest Calculated?
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.